Innovating Diagnostics and What's Next

Rhea-AI Summary

QuidelOrtho (Nasdaq: QDEL) released Episode 54 of its Science Bytes podcast on Dec. 18, 2025, featuring Jonathan Siegrist, PhD, EVP of Research & Development and CTO.

Key topics include high-sensitivity troponin for faster cardiac diagnosis, non-invasive gastrointestinal assays, rapid combo respiratory tests, advances in molecular platforms, informatics and AI, and R&D strategies to scale diagnostic innovation globally. The episode discusses how these technologies streamline clinical workflows and support timely patient care decisions.

The podcast is available on major streaming platforms and at the company website.

Key Figures

Podcast episode Episode 54 Science Bytes podcast series highlighting diagnostic innovation

Market Reality Check

$28.95 Last Close

Volume Volume 789,647 is about 0.74x the 20-day average of 1,067,110, indicating quieter trading pre-announcement. normal

Technical Price at $29.39 was trading slightly above the $28.75 200-day moving average ahead of the podcast release.

Peers on Argus 1 Down

Among close peers, INSP showed notable downside momentum at about -21.59%, while others like PRCT, ATEC, and HAE had smaller mixed moves, suggesting QDEL’s setup was more stock-specific than sector-driven.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 24	Investor conferences	Positive	+9.2%	Upcoming participation in two early-December 2025 healthcare investor conferences.
Nov 20	Educational podcast	Positive	+1.5%	Science Bytes episode on early diabetes detection and emerging biomarkers.
Nov 18	Product launch	Positive	+0.8%	Launch of QUICKVUE Influenza + SARS rapid combo test for professional use.
Nov 05	Quarterly earnings	Negative	+0.9%	Q3 2025 results with large goodwill impairment driving a substantial net loss.
Nov 03	Regulatory clearance	Positive	+2.7%	FDA 510(k) clearance for VITROS hs Troponin I cardiac assay for MI diagnosis.

Pattern Detected

Recent news, especially product and regulatory updates plus investor events, has generally coincided with modest positive next-day price moves, while earnings with large non-cash charges still saw a small positive reaction.

Recent Company History

Over the past two months, QuidelOrtho has reported several key developments. On Nov 3, 2025, it received FDA 510(k) clearance for the VITROS hs Troponin I Assay, aiding myocardial infarction diagnosis. Q3 2025 results on Nov 5, 2025 showed $700M revenue alongside a $701M goodwill impairment and a $733M GAAP net loss. Subsequent podcast and diagnostic product news, plus participation in December 2025 investor conferences, all corresponded with modest positive price reactions, setting a backdrop of steady, news-supported interest ahead of this innovation-focused podcast episode.

Market Pulse Summary

This announcement centers on a Science Bytes podcast episode discussing 2025 diagnostic trends, including high-sensitivity troponin testing, non-invasive assays, respiratory combo tests, and the role of informatics and AI. In recent months, QuidelOrtho combined such thought leadership with concrete milestones like regulatory clearances and product launches. Investors may watch how these themes connect to future product pipelines, revenue contributions, and follow-on regulatory or commercial updates rather than viewing the podcast as a standalone catalyst.

Key Terms

in vitro diagnostics medical

"QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has"

In vitro diagnostics are medical tests performed on samples taken from the body—such as blood, urine or tissue—using instruments or kits outside the patient to detect disease, measure biomarkers or guide treatment decisions. They matter to investors because sales, regulatory approvals, reimbursement rules and adoption rates drive companies’ revenue and margins much like product launches and consumer demand in other industries; advances can create growth or disruption in healthcare markets.

molecular diagnostics medical

"Dr. Siegrist is a recognized leader in molecular diagnostics and biomedical engineering,"

Molecular diagnostics are laboratory tests that look for specific molecules — such as genes, pieces of DNA or RNA, or proteins — to detect disease, predict risk, or guide treatment choices. For investors, these tests matter because they can change how illnesses are diagnosed and treated, create recurring revenue through specialized tests and companion products, and face clear regulatory and reimbursement pathways that drive commercial value; think of them as reading a biological barcode to inform medical decisions.

biomedical engineering medical

"recognized leader in molecular diagnostics and biomedical engineering, driving innovation"

Biomedical engineering applies engineering skills to create and improve medical devices, diagnostic tools, and health technologies — for example artificial joints, imaging machines, lab instruments, and wearable monitors. It matters to investors because these innovations can open new markets, drive revenue and profit, or cut healthcare costs, while technical challenges, clinical testing and regulatory approval shape how quickly and reliably a product can reach patients; think of investing in a company building a better, faster tool that changes how care is delivered.

high-sensitivity troponin testing medical

"Faster cardiac care: High-sensitivity troponin testing accelerates diagnosis and treatment"

A blood test that measures very low levels of troponin, a protein released when heart muscle is injured, allowing doctors to detect heart attacks and other cardiac damage much earlier and more accurately than older tests. For investors, this matters because wider use of high-sensitivity troponin testing can change demand for lab equipment and test kits, speed patient flow and costs in hospitals, affect reimbursement and clinical guidelines, and influence the market outlook for diagnostics and related healthcare services.

non-invasive medical

"Non-invasive solutions: New assays enhance gastrointestinal health without invasive procedures."

Non-invasive describes medical tests, treatments or devices that work from outside the body without cutting, inserting instruments, or implanting materials — for example external imaging, skin patches, or breath and saliva tests. For investors, non-invasive solutions often mean lower procedural risk, faster regulatory paths, easier manufacturing and broader patient acceptance, which can translate into quicker market uptake, lower costs and different revenue potential compared with invasive alternatives.

assays medical

"Non-invasive solutions: New assays enhance gastrointestinal health without invasive"

Assays are laboratory tests that detect or measure a specific substance, molecule, or biological activity—for example whether a drug reaches its target, how much of a chemical is present, or whether a diagnostic marker exists. Think of them like quality-control checks or sensors that tell you if an ingredient and its amount meet a standard. For investors, assay results drive clinical decisions, regulatory approval, manufacturing quality and timelines, all of which affect a company’s value and risk.

informatics technical

"molecular platforms, informatics and AI enable smarter, more personalized care."

Informatics is the practice of collecting, organizing and turning large sets of data into useful information using software and rules, often in fields like healthcare or business. For investors, it matters because better information systems act like a reliable map and traffic report for a company: they speed decision-making, reduce costly errors, improve product development and regulatory tracking, and can therefore influence revenue, costs and risk.

AI technical

"platforms, informatics and AI enable smarter, more personalized care."

Artificial intelligence (AI) is technology that enables machines to mimic human thinking and learning, allowing them to analyze information, recognize patterns, and make decisions. For investors, AI matters because it can improve how businesses operate, create new products, or identify opportunities faster and more accurately than humans alone, potentially impacting company success and market trends.

AI-generated analysis. Not financial advice.

SAN DIEGO, Dec. 18, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released Episode 54 of its Science Bytes podcast, featuring Jonathan Siegrist, PhD, Executive Vice President of Research & Development and Chief Technology Officer at QuidelOrtho. Dr. Siegrist is a recognized leader in molecular diagnostics and biomedical engineering, driving innovation and next-generation diagnostic solutions.

Key insights include:

• Faster cardiac care: High-sensitivity troponin testing accelerates diagnosis and treatment for cardiac patients.
• Non-invasive solutions: New assays enhance gastrointestinal health without invasive procedures.
• Rapid response: Combo tests help clinicians manage respiratory surges efficiently.
• Next-gen diagnostics: Advances in molecular platforms, informatics and AI enable smarter, more personalized care.
• Innovation at scale: R&D strategies are shaping diagnostics to meet global healthcare challenges.

In the episode titled "2025 Diagnostic Trends and Innovations," Dr. Siegrist joins host Josh Casey to explore the transformative technologies redefining patient care. From high-sensitivity troponin testing for faster cardiac decisions to non-invasive assays improving gastrointestinal health, rapid combo tests for respiratory surges, and advances in molecular diagnostics, informatics and AI – these innovations are streamlining workflows, guiding timely decisions and improving outcomes across the continuum of care.

This episode highlights how cutting-edge research and collaboration are driving diagnostic breakthroughs that empower clinicians and improve patient outcomes worldwide.

The QuidelOrtho Science Bytes podcast is available on major streaming platforms and at: https://www.quidelortho.com/global/en/resources/podcasts/quidelortho-science-bytes.

Forward-Looking Statements

This Science Bytes Podcast ("Podcast") of QuidelOrtho Corporation ("QuidelOrtho") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are any statement contained herein that is not strictly historical, including, but not limited to, QuidelOrtho's commercial and other strategic goals, and related assumptions, including research & development initiatives, and other future plans, objectives, strategies, expectations and intentions. Without limiting the foregoing, the words "may," "will," "could," "would," "should," "might," "expect," "anticipate," "believe," "estimate," "plan," "intend," "goal," "project," "strategy," "future," "continue," "aim," "strive," "seek" or similar words, expressions or the negative of such terms or other comparable terminology are intended to identify forward-looking statements. Such statements are based on the beliefs and expectations of QuidelOrtho's management as of the date of this Podcast and are subject to significant known and unknown risks and uncertainties. Actual results or outcomes may differ significantly from those set forth or implied in the forward-looking statements. The following factors, among others, could cause actual results or outcomes to differ from those set forth or implied in the forward-looking statements: failure to exercise the option to acquire or complete the proposed acquisition of LEX Diagnostics on the anticipated timeline, or at all, including risks and uncertainties related to LEX Diagnostics' ability to secure FDA clearance and satisfy other customary closing conditions and provisions; inability to realize the anticipated benefits of acquisitions; and delays in the development of or failures or delays in the receipt of approvals for new or enhanced products. Additional risks and factors are discussed in QuidelOrtho's Annual Report on Form 10-K for the fiscal year ended December 29, 2024 and subsequent reports filed with the Securities and Exchange Commission (the "Commission"), including under Part I, Item 1A, "Risk Factors" of the Form 10-K. You should not rely on forward-looking statements as predictions of future events because these statements are based on assumptions that may not come true and are speculative by their nature. All forward-looking statements are based on information currently available to QuidelOrtho and speak only as of the date of this Podcast. QuidelOrtho undertakes no obligation to update any of the forward-looking information or time-sensitive information included in this Podcast, whether as a result of new information, future events, changed expectations or otherwise, except as required by law.

About QuidelOrtho Corporation

With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, delivering fast, accurate and reliable results that help improve patient outcomes – from the point of care to lab, clinic to hospital. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.

Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@QuidelOrtho.com

Media Contact:
D. Nikki Wheeler
Senior Director, Corporate Communications
Media@QuidelOrtho.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/innovating-diagnostics-and-whats-next-302645368.html

SOURCE QuidelOrtho Corporation

FAQ

What did QuidelOrtho (QDEL) announce on Dec. 18, 2025?

QuidelOrtho published Episode 54 of its Science Bytes podcast featuring Jonathan Siegrist discussing diagnostic trends and innovations.

Who is the guest on QuidelOrtho Science Bytes Episode 54 (QDEL)?

Jonathan Siegrist, PhD, Executive Vice President of Research & Development and CTO at QuidelOrtho.

What diagnostic topics does QDEL cover in the Dec. 18, 2025 podcast?

High-sensitivity troponin for cardiac care, non-invasive gastrointestinal assays, rapid combo respiratory tests, and molecular, informatics and AI advances.

How can investors listen to QuidelOrtho (QDEL) Science Bytes Episode 54?

The episode is on major streaming platforms and available on the company's website resource page.

Does the QDEL podcast episode announce financial results or guidance?

No; the episode discusses diagnostic technology trends and R&D topics, not financial results or guidance.